Intriguingly, prognostic factors of CML such as blast percentage (86% vs. 69%) and BCR::ABL1 /ABL1IS ratio (97.6% vs. 65.4%) were significantly higher in FLT3+ BP patients than FLT3− BP patients. Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.